697 related articles for article (PubMed ID: 20565946)
1. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life.
Johnson RW; Bouhassira D; Kassianos G; Leplège A; Schmader KE; Weinke T
BMC Med; 2010 Jun; 8():37. PubMed ID: 20565946
[TBL] [Abstract][Full Text] [Related]
2. Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination.
Johnson RW
Aging Clin Exp Res; 2009 Jun; 21(3):236-43. PubMed ID: 19571648
[TBL] [Abstract][Full Text] [Related]
3. Public health impact of herpes zoster vaccination on older adults in Singapore: a modeling study.
Oh H; Tan C; Williams C; Giannelos N; Ng C
Hum Vaccin Immunother; 2024 Dec; 20(1):2348839. PubMed ID: 38804600
[TBL] [Abstract][Full Text] [Related]
4. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.
Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY
J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400
[TBL] [Abstract][Full Text] [Related]
5. Impact of herpes zoster and postherpetic neuralgia on the quality of life of Germans aged 50 or above.
Curran D; Schmidt-Ott R; Schutter U; Simon J; Anastassopoulou A; Matthews S
BMC Infect Dis; 2018 Oct; 18(1):496. PubMed ID: 30285731
[TBL] [Abstract][Full Text] [Related]
6. Public health impact of herpes zoster vaccination on older adults in Hong Kong.
Chan PKS; Wong MCS; Chan M; Ching K; Giannelos N; Ng C
Hum Vaccin Immunother; 2023 Dec; 19(1):2176065. PubMed ID: 36854447
[TBL] [Abstract][Full Text] [Related]
7. Vaccination: a new option to reduce the burden of herpes zoster.
Mick G
Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716
[TBL] [Abstract][Full Text] [Related]
8. Impact of Herpes Zoster and Post-Herpetic Neuralgia on Health-Related Quality of Life in Japanese Adults Aged 60 Years or Older: Results from a Prospective, Observational Cohort Study.
Mizukami A; Sato K; Adachi K; Matthews S; Holl K; Matsuki T; Kaise T; Curran D
Clin Drug Investig; 2018 Jan; 38(1):29-37. PubMed ID: 29086340
[TBL] [Abstract][Full Text] [Related]
9. How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
Han R; Gomez JA; de Veras B; Pinto T; Guzman-Holst A; Nieto J; van Oorschot DAM
Hum Vaccin Immunother; 2023 Dec; 19(1):2164144. PubMed ID: 36821856
[TBL] [Abstract][Full Text] [Related]
10. Challenges in quantifying the patient-reported burden of herpes zoster and post-herpetic neuralgia in the UK: learnings from the Zoster Quality of Life (ZQOL) study.
Carroll S; Gater A; Abetz-Webb L; Smith F; Demuth D; Mannan A
BMC Res Notes; 2013 Nov; 6():486. PubMed ID: 24274819
[TBL] [Abstract][Full Text] [Related]
11. [Herpes Zoster and its prevention in Italy. Scientific consensus statement].
Franco E; Gabutti G; Bonanni P; Conversano M; Stefano Valente ME; Ferro A; Icardi G; Antonio Volpi ML; Maggi S; Rossi A; Scotti S; Vitale F; Greco D;
Ig Sanita Pubbl; 2014; 70(1):111-27. PubMed ID: 24770367
[TBL] [Abstract][Full Text] [Related]
12. Herpes zoster and postherpetic neuralgia.
Johnson RW
Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):21-6. PubMed ID: 20192714
[TBL] [Abstract][Full Text] [Related]
13. The impact of varicella zoster virus: chronic pain.
Opstelten W; McElhaney J; Weinberger B; Oaklander AL; Johnson RW
J Clin Virol; 2010 May; 48 Suppl 1():S8-13. PubMed ID: 20510265
[TBL] [Abstract][Full Text] [Related]
14. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status.
Marin M; Yawn BP; Hales CM; Wollan PC; Bialek SR; Zhang J; Kurland MJ; Harpaz R
Hum Vaccin Immunother; 2015; 11(5):1157-64. PubMed ID: 25806911
[TBL] [Abstract][Full Text] [Related]
15. [Therapy of herpes zoster and postherpetic neuralgia].
Hüning S; von Dücker L; Kohl WK; Nashan D
Hautarzt; 2019 Aug; 70(8):645-656. PubMed ID: 31270550
[TBL] [Abstract][Full Text] [Related]
16. [Zoster and postherpetic neuralgia: vaccine prevention is available].
Belmin J; Jarzebowski W; Lafuente-Lafuente C
Geriatr Psychol Neuropsychiatr Vieil; 2015 Sep; 13 Suppl 2():15-20. PubMed ID: 26967927
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of vaccination against herpes zoster.
de Boer PT; Wilschut JC; Postma MJ
Hum Vaccin Immunother; 2014; 10(7):2048-61. PubMed ID: 25424815
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.
Préaud E; Uhart M; Böhm K; Aidelsburger P; Anger D; Bianic F; Largeron N
Hum Vaccin Immunother; 2015; 11(4):884-96. PubMed ID: 25933182
[TBL] [Abstract][Full Text] [Related]
19. Nutritional factors in herpes zoster, postherpetic neuralgia, and zoster vaccination.
Chen JY; Chang CY; Lin YS; Hu ML
Popul Health Manag; 2012 Dec; 15(6):391-7. PubMed ID: 23088666
[TBL] [Abstract][Full Text] [Related]
20. Shingles (Herpes Zoster) Vaccine (Zostavax(®)): A Review in the Prevention of Herpes Zoster and Postherpetic Neuralgia.
Keating GM
BioDrugs; 2016 Jun; 30(3):243-54. PubMed ID: 27189459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
